
    
      Phase 2 is planned to recruit approximately 50 or more eligible subjects in order to obtain
      data from 40 evaluable patients. Anticipated completion date in Dec 2018. Recruitment
      completed.

      Phase 3 is planned to recruit 350 patients. Anticipated completion date in Dec 2022. Not yet
      recruiting.
    
  